-
Sector Analysis
Pulmonary Arterial Hypertension Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029
Pulmonary Arterial Hypertension Market Overview The Pulmonary Arterial Hypertension (PAH) market size across the 7MM was valued at $4.6 billion in 2019 and is forecast to grow at a CAGR of more than 4% during 2019-2029. Pulmonary Arterial Hypertension Market Outlook To gain more information on the Pulmonary Arterial Hypertension market forecast, download a free report sample The Pulmonary Arterial Hypertension market research report provides an overview of PAH, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. Market Size (2019)...
-
Product Insights
Net Present Value Model: Pravachol
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Pravachol Drug Details Pravastatin sodium (Pravachol,...
-
Sector Analysis
Pulmonary Arterial Hypertension – Epidemiology Forecast to 2029
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by vascular proliferation and remodeling of the small pulmonary arteries (Humbert et al., 2004; Humbert et al., 2010; Simonneau et al., 2004). In PAH, blood vessels in the lungs are narrowed, blocked, or destroyed. The damage slows blood flow through the lungs (Mayo Clinic, 2020). This results in progressively increasing pulmonary vascular resistance, leading to an increase in pulmonary arterial pressure (Humbert et al., 2004, 2010; Simonneau et al., 2004)....
-
Sector Analysis
EpiCast Report: Pulmonary Arterial Hypertension – Epidemiology Forecast to 2026
PAH is a rare and severe condition characterized by vascular proliferation and remodeling of the small pulmonary arteries. This results in progressively increasing pulmonary vascular resistance, leading to an increase in pulmonary arterial pressure. The disease typically results in right-sided heart failure and premature death To forecast the diagnosed incident and diagnosed prevalent cases of PAH in the 7MM, GlobalData epidemiologists selected nationally representative, registry-based studies and Ministry of Health statistics studies that provided the diagnosed incidence and/or diagnosed prevalence...
-
Sector Analysis
OpportunityAnalyzer: Pulmonary Arterial Hypertension – Opportunity Analysis and Forecasts to 2026
Pulmonary arterial hypertension (PAH) is a rare, fatal cardiopulmonary disease with an annual mortality rate of 15%. The disease is a subset (Group 1) within the World Health Organization’s (WHO’s) classification of the different types of pulmonary hypertension (PH). PAH is characterized by an abnormal rise in the resting mean pulmonary arterial pressure (>25mmHg compared with normal levels of around 14mmHg). This increased pressure is caused by pulmonary arterial obstruction due to endothelial dysfunction and vascular remodeling, and leads to...
-
Sector Analysis
EpiCast Report: Pulmonary Arterial Hypertension – Epidemiology Forecast to 2024
PAH is a rare and severe condition characterized by vascular proliferation and remodeling of the small pulmonary arteries. This results in progressively increasing pulmonary vascular resistance, leading to an increase in pulmonary arterial pressure. The disease typically results in right-sided heart failure and premature death. PAH can be idiopathic, heritable, or associated with different conditions such as connective tissue disease (CTD), congenital heart disease (CHD), human immunodeficiency virus (HIV) infection, and exposure to toxins or drugs. PAH occurs twice as...